文献速递系统性红斑狼疮

靶向BCMA的CAR-T细胞疗法可有效诱导难治性狼疮肾炎疾病缓解

BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis.
PubMed 文献 · Ann Rheum Dis · 2025-07-18

这项开放标签单臂临床试验评估了抗B细胞成熟抗原(BCMA)CAR-T细胞治疗难治性狼疮肾炎(LN)的安全性和疗效。7例活检确诊LN患者接受环磷酰胺联合氟达拉滨清淋后输注CAR-T细胞,中位随访9个月,SLEDAI-2K评分从基线中位18分降至末次随访0分,5/7例达到DORIS完全缓解,仅1例1级细胞因子释放综合征,无ICANS或严重感染。

要点

  • 7例难治性LN患者接受抗BCMA CAR-T治疗,中位随访9个月,5/7例达到DORIS完全缓解。
  • SLEDAI-2K评分从基线中位18分(范围10-22)降至末次随访0分(范围0-4)。
  • 仅1例1级细胞因子释放综合征,无ICANS或严重感染,低丙种球蛋白血症常见。

核心结论

  • 抗BCMA CAR-T疗法可安全有效地帮助LN患者诱导并维持疾病缓解状态,提示仅靶向BCMA的策略通过CAR产品治疗体液免疫异常的自身免疫病具有潜在可行性。

研究设计与样本

  • 开放标签、单臂临床试验,评估抗BCMA CAR-T细胞治疗难治性LN患者。
  • CAR-T细胞在环磷酰胺和氟达拉滨清淋治疗后输注。
  • 患者定期随访进行临床评估并收集实验室指标,部分患者接受重复肾活检和单细胞RNA测序。
  • 主要终点为单次输注的安全剂量和不良事件发生情况,次要终点关注疗效(如SLEDAI-2000变化)。

主要发现

  • 共纳入7例活检确诊LN患者,中位随访9个月。
  • 外周B细胞在输注后第一个月内被有效清除,除1例患者外均在3个月内恢复。
  • 低丙种球蛋白血症在本研究中频繁观察到。
  • 仅记录到1例1级细胞因子释放综合征,未报告免疫效应细胞相关神经毒性综合征或严重感染。
  • SLEDAI-2K评分从基线中位18分(范围10-22)降至末次随访0分(范围0-4),7例中5例达到DORIS完全缓解。

关键数值与推荐

  • SLEDAI-2K评分从基线中位18分(范围10-22)降至末次随访0分(范围0-4)。
  • 7例中5例达到DORIS完全缓解。
  • 仅1例1级细胞因子释放综合征,无ICANS或严重感染报告。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to evaluate the safety and efficacy of anti-B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells in treating refractory lupus nephritis (LN). METHODS: This is an open-label, single-arm clinical trial assessing anti-BCMA CAR T cells in treating refractory LN patients. CAR T cells were infused following lymphodepletion therapy with cyclophosphamide and fludarabine. Patients were regularly followed up, in which clinical assessments were performed and laboratory indices were collected. Repeated renal biopsies and single cell RNA sequencing in certain patients were performed to help evaluate the therapeutic efficacy. The primary endpoints were the safe dosage of single infusion and the occurrence of adverse events, while the secondary endpoints focused on the therapeutic efficacy (eg, changes of Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2000]). RESULTS: Seven biopsy-confirmed LN patients were enrolled in this study with a median follow-up of 9 months, whose peripheral B cells were effectively eliminated within the first month postinfusions and restored within 3 months except one patient. Hypogammaglobulinemia was frequently observed in this study. Only one case of grade 1 cytokine release syndrome was noted, and no immune effector cell-associated neurotoxicity syndrome or severe infection was reported. SLEDAI-2K scores decreased from a median of 18 (range 10-22) at baseline to 0 (range 0-4) at the last follow-up, and 5 out of 7 patients achieved definition of remission in systemic lupus erythematosus (DORIS) complete remission. Decreased deposition of immune complex, reduced clonal abundance, and alleviated proinflammatory status of peripheral lymphocytes were also observed in repeated renal biopsy and transcriptomic analyses,. CONCLUSIONS: Anti-BCMA CAR T therapy can help LN patients inducing and maintaining disease remission status safely and effectively, which indicated the potential feasibility of the BCMA-only-targeting strategy in treating autoimmune diseases with abnormal humoral immune responses through CAR products.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hu Z, Cai S, Yu Y, et al. BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann Rheum Dis. 2025. PMID: 40681435. doi:10.1016/j.ard.2025.06.2128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。